BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 21, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Viva in vivo! At EHA, in vivo CAR T data continues to impressBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
BioWorld Science, Cancer RSS Feed RSS

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow
Immuno-oncology

NI-3201, an example of effective PD-L1-dependent CD28 costimulation

Jan. 21, 2025
Cancer immunotherapy has represented a significant advancement in cancer treatment; however, many patients experience relapse or develop resistance to this treatment. Bispecific antibodies that selectively engage T-cell costimulatory molecules have emerged as a novel therapeutic strategy to overcome the limitations of immunotherapy.
Read More
Cancer

SIAIS-562055, a SOS1 PROTAC with activity in models of KRAS-mutant tumors and BCR-ABL-positive leukemia

Jan. 21, 2025
Son of sevenless homolog 1 (SOS1) is an essential guanine nucleotide exchange factor (GEF) in KRAS-driven tumors, and it also functions as a downstream node protein of BCR-ABL, suggesting its critical role in the pathogenesis of chronic myeloid leukemia (CML). Investigators at Shanghaitech University have reported the discovery and preclinical characterization of a novel potent SOS1 proteolysis targeting chimera (PROTAC) – SIAIS-562055 – being developed as an anticancer agent.
Read More
Cancer

Chia Tai Tianqing Pharmaceutical divulges new KIF18A inhibitors

Jan. 20, 2025
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Valo Health patents new PARP-1 inhibitors

Jan. 20, 2025
Valo Health Inc. has disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Read More
Various pills laid across a target
Cancer

YTHDF2 unveiled as target for B-cell malignancies

Jan. 20, 2025
City of Hope conducted RNAseq analysis of patient samples with B-cell acute lymphoblastic leukemia (B-ALL), which revealed that among the m6A machinery genes, YTHDF2, which encodes YTH N6-methyladenosine RNA binding protein F2, was the most significantly overexpressed gene.
Read More
Colorectal cancer 3D illustration
Cancer

Multitarget kinase inhibitor shows efficacy in PDX-derived colorectal cancer cells

Jan. 20, 2025
Researchers from the National Health Research Institutes of Taiwan described the efficacy of BPR1J481, a multitarget tyrosine kinase inhibitor in PDX-derived colorectal cancer cells, which retain the original PDX tumor characteristics.
Read More
Cancer

[177Lu]DOTA-2P(FAPI)2 transforms the TME, increases sensitivity to PD-1/PD-L1 immunotherapy

Jan. 20, 2025
[68Ga]/[177Lu]DOTA-2P(FAPI)2 is a novel dimeric FAP-targeting radiopharmaceutical that has demonstrated increased tumor uptake and prolonged retention in different types of cancer models.
Read More
Cancer

Korea University patents chromene-benzimidazole derivatives for cancer

Jan. 17, 2025
Korea University Research & Business Foundation Sejong Campus have prepared and tested new chromene-benzimidazole derivatives.
Read More
Breast cancer illustration
Immuno-oncology

New granzyme B-based immunotoxin targeting breast cancer, including TNBC

Jan. 17, 2025
Researchers have developed an innovative immunotoxin (a fusion protein called GrB-Fc-KS49) designed to target epithelial membrane protein-2 (EMP2), a biomarker overexpressed in more than 75% of breast cancer cases, including triple-negative breast cancer (TNBC).
Read More
Cancer

HSP60 inhibition as an approach for neuroendocrine prostate cancer

Jan. 17, 2025
It is known that mitochondrial unfolded protein response (UPRmt), initiated by the transcription factor ATF5, maintains protein homeostasis under stress conditions by folding denatured proteins, folding newly imported proteins into the mitochondria or by degrading damaged proteins.
Read More
Previous 1 2 … 215 216 217 218 219 220 221 222 223 … 3708 3709 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • UTRN gene involved in arthrogryposis, study finds

    BioWorld Science
    Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
  • Wireframe of feet and scale

    GLP-1s need technologies for long-term use

    BioWorld
    For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
  • Illustration of glucose in the blood stream

    CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

    BioWorld Science
    Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
  • Blue-gray dollar sign

    HMNC raises $50M series B to prep depression drugs for phase III

    BioWorld
    HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing